![]() |
Volumn 52, Issue 1 Suppl, 2012, Pages
|
Clinical pharmacology basis of deriving dosing recommendations for dabigatran in patients with severe renal impairment.
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ANTITHROMBIN;
BENZIMIDAZOLE DERIVATIVE;
BETA ALANINE;
DRUG DERIVATIVE;
N ((2 (((4 (AMINOIMINOMETHYL)PHENYL)AMINO)METHYL) 1 METHYL 1H BENZIMIDAZOL 5 YL)CARBONYL) N 2 PYRIDINYL BETA ALANINE;
N-((2-(((4-(AMINOIMINOMETHYL)PHENYL)AMINO)METHYL)-1-METHYL-1H-BENZIMIDAZOL-5-YL)CARBONYL)-N-2-PYRIDINYL-BETA-ALANINE;
ADULT;
AGED;
ARTICLE;
BIOLOGICAL MODEL;
BLOOD;
CLINICAL TRIAL;
COMPUTER SIMULATION;
CONTROLLED CLINICAL TRIAL;
CONTROLLED STUDY;
FEMALE;
HUMAN;
KIDNEY DISEASE;
MALE;
METABOLISM;
MIDDLE AGED;
PHASE 1 CLINICAL TRIAL;
ADULT;
AGED;
ANTITHROMBINS;
BENZIMIDAZOLES;
BETA-ALANINE;
COMPUTER SIMULATION;
FEMALE;
HUMANS;
KIDNEY DISEASES;
MALE;
MIDDLE AGED;
MODELS, BIOLOGICAL;
YOUNG ADULT;
MLCS;
MLOWN;
|
EID: 84859800192
PISSN: None
EISSN: 15524604
Source Type: Journal
DOI: 10.1177/0091270011415527 Document Type: Article |
Times cited : (74)
|
References (0)
|